These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26677205)

  • 1. Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry.
    Dite GS; MacInnis RJ; Bickerstaffe A; Dowty JG; Allman R; Apicella C; Milne RL; Tsimiklis H; Phillips KA; Giles GG; Terry MB; Southey MC; Hopper JL
    Cancer Epidemiol Biomarkers Prev; 2016 Feb; 25(2):359-65. PubMed ID: 26677205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 10-year performance of four models of breast cancer risk: a validation study.
    Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
    Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
    Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
    J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SNPs and breast cancer risk prediction for African American and Hispanic women.
    Allman R; Dite GS; Hopper JL; Gordon O; Starlard-Davenport A; Chlebowski R; Kooperberg C
    Breast Cancer Res Treat; 2015 Dec; 154(3):583-9. PubMed ID: 26589314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model.
    Dite GS; Mahmoodi M; Bickerstaffe A; Hammet F; Macinnis RJ; Tsimiklis H; Dowty JG; Apicella C; Phillips KA; Giles GG; Southey MC; Hopper JL
    Breast Cancer Res Treat; 2013 Jun; 139(3):887-96. PubMed ID: 23774992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance.
    Quante AS; Whittemore AS; Shriver T; Strauch K; Terry MB
    Breast Cancer Res; 2012 Nov; 14(6):R144. PubMed ID: 23127309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information.
    Mealiffe ME; Stokowski RP; Rhees BK; Prentice RL; Pettinger M; Hinds DA
    J Natl Cancer Inst; 2010 Nov; 102(21):1618-27. PubMed ID: 20956782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.
    Quante AS; Whittemore AS; Shriver T; Hopper JL; Strauch K; Terry MB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25956172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
    Antoniou AC; Hardy R; Walker L; Evans DG; Shenton A; Eeles R; Shanley S; Pichert G; Izatt L; Rose S; Douglas F; Eccles D; Morrison PJ; Scott J; Zimmern RL; Easton DF; Pharoah PD
    J Med Genet; 2008 Jul; 45(7):425-31. PubMed ID: 18413374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of Risk Prediction Models for Breast Cancer and
    Kenan ES; Friger M; Shochat-Bigon D; Schayek H; Bernstein-Molho R; Friedman E
    Anticancer Res; 2018 Aug; 38(8):4557-4563. PubMed ID: 30061222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a genetic risk score for Arkansas women of color.
    Starlard-Davenport A; Allman R; Dite GS; Hopper JL; Spaeth Tuff E; Macleod S; Kadlubar S; Preston M; Henry-Tillman R
    PLoS One; 2018; 13(10):e0204834. PubMed ID: 30281645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of breast cancer risk assessment tools on a French-Canadian population-based cohort.
    Jantzen R; Payette Y; de Malliard T; Labbé C; Noisel N; Broët P
    BMJ Open; 2021 Apr; 11(4):e045078. PubMed ID: 33846154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre.
    MacInnis RJ; Bickerstaffe A; Apicella C; Dite GS; Dowty JG; Aujard K; Phillips KA; Weideman P; Lee A; Terry MB; Giles GG; Southey MC; Antoniou AC; Hopper JL
    Br J Cancer; 2013 Sep; 109(5):1296-301. PubMed ID: 23942072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validating the IBIS and BOADICEA Models for Predicting Breast Cancer Risk in the Iranian Population.
    Ghoncheh M; Ziaee F; Karami M; Poorolajal J
    Clin Breast Cancer; 2017 Jun; 17(3):e113-e118. PubMed ID: 28216418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO.
    Biswas S; Tankhiwale N; Blackford A; Barrera AM; Ready K; Lu K; Amos CI; Parmigiani G; Arun B
    Breast Cancer Res Treat; 2012 May; 133(1):347-55. PubMed ID: 22270937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study.
    Evans DG; Brentnall A; Byers H; Harkness E; Stavrinos P; Howell A; ; Newman WG; Cuzick J
    J Med Genet; 2017 Feb; 54(2):111-113. PubMed ID: 27794048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan.
    Hung FH; Wang YA; Jian JW; Peng HP; Hsieh LL; Hung CF; Yang MM; Yang AS
    Sci Rep; 2019 Jul; 9(1):10229. PubMed ID: 31308460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
    Moghadasi S; Grundeken V; Janssen LAM; Dijkstra NH; Rodríguez-Girondo M; van Zelst-Stams WAG; Oosterwijk JC; Ausems MGEM; Oldenburg RA; Adank MA; Blom EW; Ruijs MWG; van Os TAM; van Deurzen CHM; Martens JWM; Schroder CP; Wijnen JT; Vreeswijk MPG; van Asperen CJ
    Clin Genet; 2018 Jan; 93(1):52-59. PubMed ID: 28589637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of the Gail model, body mass index and SNPs to predict breast cancer among women with abnormal (BI-RADS 4) mammograms.
    McCarthy AM; Keller B; Kontos D; Boghossian L; McGuire E; Bristol M; Chen J; Domchek S; Armstrong K
    Breast Cancer Res; 2015 Jan; 17(1):1. PubMed ID: 25567532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.